Male pattern hair loss, also known as androgenetic alopecia (AGA), is a widespread concern among men, characterized by a progressive decline in hair density and often beginning between adolescence and the age of 30. This condition, influenced by genetics and an excessive response to androgens, leads to changes in the hair cycle, follicular miniaturization, and inflammation. Understanding the available treatments is crucial for those seeking to combat AGA.
AGA is a genetic disorder with an excessive response to androgens. During normal hair growth, activation of the androgen receptor shortens the anagen (growth) phase. It has been proposed that excessive activation of the androgen receptor by DHT leads to progressively shorter anagen phases and follicular miniaturization. This results in shorter and thinner hair follicles that are unable to reach the surface of the scalp, creating the appearance of hair loss seen in patients with AGA.
Finasteride and dutasteride are 5-α-reductase inhibitors (5-ARIs) used in the treatment of AGA by preventing the conversion of testosterone to dihydrotestosterone (DHT) because suppression of circulating levels of DHT is thought to improve hair growth in men with AGA. The rationale behind using 5-ARIs lies in their ability to reduce the amount of circulating DHT, a hormone implicated in shortening the hair growth phase and causing follicular miniaturization. Finasteride is a type II 5-ARI used to limit the conversion of testosterone to DHT. Oral finasteride, 1 mg, daily is the only 5-ARI that has received Food and Drug Administration (FDA) approval for AGA treatment.
In two 1-year trials, 1553 men with AGA were treated with oral finasteride, 1 mg, or placebo daily, and 1215 men continued in blinded extension studies for a second year. These trials showed that finasteride led to improvement in hair counts, patient/investigator assessments of hair growth, and panel review of photographs. In a systematic review that included 12 studies, 3927 men with AGA were randomized to receive either oral finasteride or placebo.
Dutasteride, another 5-ARI, distinguishes itself by blocking both type 1 and type 2 5AR, whereas finasteride is only 5AR type 2. Dutasteride lowers serum DHT to 98% compared to 71% for finasteride (1). In addition, it is more slowly metabolized than finasteride, as evidenced by its longer half-life (time required for metabolism of 50% of the dose) in the serum. The half-life is 5 weeks for dutasteride compared to 6-8 hours for finasteride.
Read also: Applying Minoxidil Effectively
In a multicenter, open-label, prospective outpatient study, 110 Japanese men with AGA completed 52 weeks of treatment with dutasteride, 0.5 mg, daily. Hair growth, hair restoration, and global appearance of hair at 52 weeks improved from baseline in this study. In a randomized, placebo-controlled study, researchers compared the efficacy of dutasteride to finasteride. This study had a large sample size of 917 men with AGA and participants were randomized to receive dutasteride (0.02, 0.1, or 0.5 mg/d), finasteride (1 mg/d), or placebo. Dutasteride, 0.5 mg, significantly increased hair count and improved hair growth at week 24 compared with finasteride (P = .003, P = .004, and P = .002, respectively) and placebo (all P < .001). Two different meta-analyses demonstrated that oral dutasteride was more effective than oral finasteride for the treatment of male AGA. In the first meta-analysis, 23 studies were included, with 2 studies being single-group observational studies and the remaining 21 studies being randomized trials. This meta-analysis showed that taking oral dutasteride, 0.5 mg, daily led to a greater increase in total hair count after 24 weeks. The other meta-analysis found that dutasteride provided better efficacy than finasteride in treating men with AGA during a 24-week treatment period. Three articles with 576 participants were included in the meta-analysis.
Research published on topical dutasteride in treating AGA is limited to a few studies where topical dutasteride has been used as an agent in mesotherapy. In a blinded, placebo-controlled study, participants were randomized to receive 7 intradermal mesotherapy injections of either 0.05% dutasteride containing solution or 0.9% saline over 12 weeks or receive placebo. The study found that those receiving dutasteride had a statistically significant increase in mean hair count when compared with placebo (Mean Density, 7.90 hairs [95% CI, 7.14-8.66]; P ≤ .001). There was a statistically significant improvement with dutasteride in independent observer assessment (P = .001) and participants’ self-assessment (P < .001). A recent randomized, double-blind, placebo-controlled trial evaluated the use of microneedling with topical 0.01% solution dutasteride compared with saline solution over a 20-week period in men with AGA. We found only 1 study comparing topical and oral dutasteride in the treatment of AGA. A systematic review compared the findings of 5 studies with oral dutasteride and 3 studies with intralesional dutasteride. None of the included studies directly compared oral vs intralesional dutasteride. Researchers compared the mean change in hair count between oral or intralesional dutasteride and placebo, although only 1 study reported hair count for intralesional dutasteride.
For patients who are concerned about systemic adverse effects of oral dutasteride, the possibility of using dutasteride locally could potentially minimize systemic adverse effects on reproduction. In a meta-analysis comparing sexual adverse effects with oral dutasteride and intralesional dutasteride vs placebo in AGA, there were no studies that reported sexual adverse effects with intralesional dutasteride treatment.
Minoxidil is a medication that may help hair obtain growth factors by regulating blood flow to hair follicles. AGA remains the most common form of hair loss in men, with therapies ranging from over-the-counter topical minoxidil to prescription 5-alpha reductase inhibitors such as finasteride.
To address this gap, researchers conducted a Bayesian network meta-analysis encompassing 33 randomized controlled trials with 18 interventions and 1 control. The analysis evaluated monotherapy with minoxidil, finasteride, or dutasteride across 5 key outcomes, including 24- and 48-week changes in both total and terminal hair density, and a 24-week change in independent observer assessment (IOA). Relative treatment effects were quantified using pairwise comparisons and surface under the cumulative ranking curve (SUCRA) values. Among all regimens studied, oral dutasteride 0.5 mg per day ranked highest for improving total hair density at 24 weeks (SUCRA, 96.3%) and was significantly more effective than dutasteride administered via mesotherapy (mean difference [MD], 9.2 hairs/cm²; 95% CI, 5.9-12.6; P <.05). However, oral dutasteride 0.5 mg daily was not statistically different from sublingual minoxidil 5 mg per day (MD, 10.9 hairs/cm²; 95% CI, -17.8 to 39.7; P ≥.05). For terminal hair density change at 24 weeks, oral minoxidil 5 mg per day (SUCRA, 93.2%) and sublingual minoxidil 5 mg per day (SUCRA, 92.2%) were the top-ranked interventions and were not statistically different in efficacy (MD, -2.3 hairs/cm²; 95% CI, -24.1 to 19.5; P ≥.05).
Read also: Choosing Minoxidil: Drops or Foam?
Notably, Olsen and colleagues showed that 5% topical minoxidil, applied twice daily, was more effective than 2% topical minoxidil (twice daily) in direct comparisons. Minoxidil 5% remains the most effective topical FDA-approved monotherapy for male AGA. Regarding safety, oral minoxidil 5 mg/day poses greater systemic risks, with hypertrichosis occurring in approximately 49% of users compared to 25% for topical formulations (topical minoxidil 5%, twice daily) (p = 0.02) [42]. Topical minoxidil 5%, twice daily predominantly causes localized irritation or hair shedding.
Given the different mechanisms of action, oral dutasteride can be combined with topical minoxidil (and possibly with oral minoxidil). You must consult with your prescribing physician to discuss those options.
Sometimes, it is combined in a combination topical solution of both dutasteride and minoxidil.
Happy Head offers personalized, prescription-strength solutions designed just for you. Using the strongest FDA-approved ingredients, such as Finasteride and Minoxidil-we help you get real hair growth results.
Happy Head formulations use up to 8% Minoxidil, the strongest available concentration compared to OTC Minoxidil at 5%.
Read also: Effectiveness of Hims Tablets
Retinoic Acid supercharges Minoxidil to promote denser hair regrowth, while Hydrocortisone prevents irritation and redness. Furthermore, the inclusion of 2.5% Ketoconazole, an FDA-approved anti-inflammatory ingredient, offers anti-dandruff protection and supports a healthier scalp.
There have been adverse sexual health effects reported with 5-ARI use including erectile dysfunction, decreased libido, and ejaculation disorders. There is also concern for teratogenicity and potential effects on spermatogenesis.
The most common category of complications reported with finasteride use was sexual adverse effects. A recent systematic review evaluated sexual dysfunction in men taking systemic dermatologic medication. This review found that most studies with patients taking high-dose finasteride described relatively common sexual adverse effects of decreased libido, impotence, and ejaculation disorders. However, high-dose finasteride at 5 mg daily is typically used to treat BPH and is rarely used in dermatology. It is also important to note that prostate disease itself is a risk factor for erectile dysfunction, which may contribute to the development of sexual dysfunction. Among studies with men taking low-dose finasteride at 1 mg daily for AGA, there was less conclusive evidence of sexual adverse effects. Five studies included in the systematic review did not support increased risk of sexual dysfunction, while 10 studies provided evidence of increased rates of sexual adverse effects. The researchers acknowledged that this review included studies limited by sample size and methodology, with some studies not including any formal evaluation of male sexual function.
When sexual adverse events occur in patients taking finasteride, some studies have indicated that symptoms often resolve either while continuing treatment or with discontinuation of the medication. However, in recent years, there have been reports of persistent sexual (low libido, erectile dysfunction, and orgasmic dysfunction) and psychological (depression, anxiety, and suicidal ideation) symptoms that persist despite discontinuation of finasteride. This led to the coining of the term postfinasteride syndrome.
The side effects of dutasteride are similar to those reported for finasteride.
As with finasteride, dutasteride should not be taken or handled by a woman who is pregnant or who may become pregnant because of the drug’s potential to cause abnormal development of a fetus.
Oral Dutasteride: The FDA approved standard dosage of oral dutasteride is 0.5 mg per day for treatment of Benign Prostatic Hypertrophy. Most hair restoration physicians use this medication off-label for reduction of DHT twice weekly because of the long half-life of oral dutasteride. It is important to follow your doctor’s prescription regarding medication dosage and frequency of use.
Topical Dutasteride: Dosages of topical dutasteride solutions range from 0.1% to 0.3%.
tags: #dutasteride #minoxidil #topical #effectiveness
